|
|
|
|
|
非在研适应症- |
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
/ Active, not recruiting临床1期 A Phase I Study of FT576 as Monotherapy and in Combination With Daratumumab in Subjects With Relapsed/Refractory Multiple Myeloma
This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage.
100 项与 IL-15Rα x CD16a x BCMA 相关的临床结果
100 项与 IL-15Rα x CD16a x BCMA 相关的转化医学
0 项与 IL-15Rα x CD16a x BCMA 相关的专利(医药)